The Emerging Role of Circulating Tumor DNA in the Management of Breast Cancer

Shoukry, Mira; Broccard, Sacha; Kaplan, Jamie; Gabriel, Emmanuel

doi:10.3390/cancers13153813

Cited by 17 publications

(8 citation statements)

References 45 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several components of the tumor can be analyzed with liquid biopsy samples, such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs) and tumor-educated platelets (TEPs) and exosomes. While TEPs and exosomes are currently studied primarily as diagnostic tools, ctDNA and CTCs show promising results in assessing response to treatment and predicting resistance in early breast cancer [ 137 , 138 , 139 , 140 , 141 , 142 ].…”

Section: Predictive Biomarkers Under Investigationmentioning

confidence: 99%

Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine

Derouane

Marcke

Berlière

et al. 2022

Cancers

View full text Add to dashboard Cite

Pathological complete response (pCR) after neoadjuvant chemotherapy in patients with early breast cancer is correlated with better survival. Meanwhile, an expanding arsenal of post-neoadjuvant treatment strategies have proven beneficial in the absence of pCR, leading to an increased use of neoadjuvant systemic therapy in patients with early breast cancer and the search for predictive biomarkers of response. The better prediction of response to neoadjuvant chemotherapy could enable the escalation or de-escalation of neoadjuvant treatment strategies, with the ultimate goal of improving the clinical management of early breast cancer. Clinico-pathological prognostic factors are currently used to estimate the potential benefit of neoadjuvant systemic treatment but are not accurate enough to allow for personalized response prediction. Other factors have recently been proposed but are not yet implementable in daily clinical practice or remain of limited utility due to the intertumoral heterogeneity of breast cancer. In this review, we describe the current knowledge about predictive factors for response to neoadjuvant chemotherapy in breast cancer patients and highlight the future perspectives that could lead to the better prediction of response, focusing on the current biomarkers used for clinical decision making and the different gene signatures that have recently been proposed for patient stratification and the prediction of response to therapies. We also discuss the intratumoral phenotypic heterogeneity in breast cancers as well as the emerging techniques and relevant pre-clinical models that could integrate this biological factor currently limiting the reliable prediction of response to neoadjuvant systemic therapy.

show abstract

Section: Predictive Biomarkers Under Investigationmentioning

confidence: 99%

Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine

Derouane

Marcke

Berlière

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…The major tumor component that is usually extracted for the identification of tumor characteristics is circulating tumor cells (CTCs) ( 71 ). Except for the CTCs, cell-free DNA (cfDNA), ctDNA ( 72 , 73 ), and c-miRNAs among other circulating non-coding RNAs ( 74 ) can be used as LB markers ( 13 ). The advancement of NGS and digital genomic approaches made biomarkers such as c-RNAs, circulating extracellular vesicles, tumor-educated platelets, proteins, etc.…”

Section: Liquid Biopsy In Breast Cancermentioning

confidence: 99%

Potential utility of miRNAs for liquid biopsy in breast cancer

et al. 2022

View full text Add to dashboard Cite

Breast cancer (BC) remains the most prevalent malignancy due to its incidence rate, recurrence, and metastasis in women. Conventional strategies of cancer detection– mammography and tissue biopsy lack the capacity to detect the complete cancer genomic landscape. Besides, they often give false- positive or negative results. The presence of this and other disadvantages such as invasiveness, high-cost, and side effects necessitates developing new strategies to overcome the BC burden. Liquid biopsy (LB) has been brought to the fore owing to its early detection, screening, prognosis, simplicity of the technique, and efficient monitoring. Remarkably, microRNAs (miRNAs)– gene expression regulators seem to play a major role as biomarkers detected in the samples of LB. Particularly, miR-21 and miR-155 among other possible candidates seem to serve as favorable biomarkers in the diagnosis and prognosis of BC. Hence, this review will assess the potential utility of miRNAs as biomarkers and will highlight certain promising candidates for the LB approach in the diagnosis and management of BC that may optimize the patient outcome.

show abstract

“…Unfortunately, there is a lack of effective clinical markers to help detect patients' recurrences and metastases in early stage. In recent years, some studies [ 2 – 4 ] have shown that the detection of ctDNA, long noncoding RNA, and modulated microRNAs in patients' body fluids can be detected by liquid biopsy for the recurrences and metastases of patients in early stage and is a promising prognostic marker. However, these marker detection with these methods are expensive, the detection methods are not standardized, they are still in research stage, and they have not been applied in clinical practice as a method to monitor tumor metastasis.…”

Section: Introductionmentioning

confidence: 99%

Changes of Tumor Markers in Patients with Breast Cancer during Postoperative Adjuvant Chemotherapy

et al. 2022

View full text Add to dashboard Cite

Objective. Serum tumor marker (STM) elevation can detect metastasis earlier than imaging diagnosis and, although not recommended by guidelines, is still widely used in clinical practice for postoperative follow-up of breast cancer patients. The purpose of this study was to investigate the change rules of CEA and CA153 in patients with HER2-negative breast cancer during postoperative adjuvant chemotherapy and their influencing factors. Materials and Methods. The medical records of patients with HER2-negative early breast cancer who visited Xuanwu Hospital from September 2018 to June 2021 were retrospectively analyzed. Demographic characteristics and baseline data of CEA and CA153 at initial diagnosis were collected. Data of CEA, CA153, biochemistry (including ALT, AST, rGT, triglycerides, cholesterol, and blood glucose) and blood routine (including white blood cells, neutrophils, monocytes, lymphocytes, and platelets) were also collected before chemotherapy, at the end of chemotherapy and more than 3 months after the end of chemotherapy. LY/MONO, NEUT/LY, PLT/LY, and systemic immune inflammation index (SII) were calculated and statistically analyzed using SPSSAU software. Results. A total of 90 patients were enrolled, all of whom were female, with a mean age of 55.11 ± 10.60 y. The value of CEA at initial diagnosis was 2.10 ± 1.11 ng/mL, and high expression was mostly correlated with past history of chronic diseases and tumor lymph node metastasis; the value of CA153 was 11.80 ± 6.60 U/mL, and high expression was correlated with high SII at initial diagnosis. Surgery did not affect the values of serum CEA and CA153. At the end of chemotherapy, CEA and CA153 were 2.68 ± 1.34 ng/mL and 18.51 ± 8.50 U/mL, respectively, which were significantly increased compared with those before chemotherapy, and were linearly correlated with the values before chemotherapy. They decreased (CEA 2.45 ± 1.19 ng/mL, CA153 10.87 ± 5.96 U/mL) again three months after the end of chemotherapy, manifested as “spiking” phenomenon, which was associated with lymph node metastasis at diagnosis, body metabolic disorders, and chronic inflammatory status. Conclusion. CEA and CA153 were increased presenting as “spiking” phenomena in patients with early HER2-negative breast cancer during postoperative adjuvant chemotherapy, and the peak of increase was linearly correlated with the indicators before chemotherapy. Clinical attention should be paid to this change to avoid excessive diagnosis and treatment leading to medical resource consumption.

show abstract

The Emerging Role of Circulating Tumor DNA in the Management of Breast Cancer

Cited by 17 publications

References 45 publications

Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine

Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine

Potential utility of miRNAs for liquid biopsy in breast cancer

Changes of Tumor Markers in Patients with Breast Cancer during Postoperative Adjuvant Chemotherapy

Contact Info

Product

Resources

About